A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC
D933IC00001
Phase 1 other active
Quick answer
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC for Metastatic Non-Small Cell Lung Cancer (NSCLC) is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1
- Modality
- other
- Status
- active